Beta-blocker use in decompensated heart failure

被引：2

作者：

Alharethi K. ^{[1
]}

Hershberger R.E. ^{[1
]}

机构：

[1] Division of Cardiology, UHN-62, Oregon Health and Science University, Portland, OR 97239

来源：

Current Heart Failure Reports | 2006年 / 3卷 / 2期

关键词：

Chronic Heart Failure; Metoprolol; Dobutamine; Carvedilol; Milrinone;

D O I：

10.1007/s11897-006-0005-y

中图分类号：

学科分类号：

摘要：

Despite the current advances in treatment, acute decompensated heart failure accounts for more than 1 million hospital admissions annually. Many of the patients hospitalized are already receiving long-term treatment with β-blockers. For patients who receive full dose β-blocker therapy and suffer acute decompensated heart failure, clinicians face two key questions: what to do, if anything, with the dosage of β-blocker and what is the best way to integrate inotropic and β-blocker therapies for patients who require inotropes. This article discusses these issues and reviews the available literature. Because these topics have received little systematic evaluation, we also present our clinical approaches to these problems. Copyright © 2006 by Current Science Inc.

引用

页码：75 / 80

页数：5

共 43 条

[1]

Packer M., Coats A.J., Fowler M.B., Et al., Effect of carvedilol on survival in severe chronic heart failure, N Engl J Med, 344, pp. 1651-1658, (2001)

[2]

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HP), Lancet, 353, pp. 2001-2007, (1999)

[3]

Brophy J.M., Joseph L., Rouleau J.L., Beta-blockers in congestive heart failure. A Bayesian meta-analysis, Ann Intern Med, 134, pp. 550-560, (2001)

[4]

Packer M., Bristow M.R., Cohn J.N., Et al., The effect of carvedilol on morbidity and mortality in patients with chronic heart failure, N Engl J Med, 334, pp. 1349-1355, (1996)

[5]

Heart Disease and Stroke Statistics - 2005 Update, (2005)

[6]

Abraham W.T., Adams K.F., Fonarow G.C., Et al., In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE), J Am Coll Cardiol, 46, pp. 57-64, (2005)

[7]

O'Connor C.M., Stough W.G., Gallup D.S., Et al., Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: Observations from the IMPACT-HF registry, J Card Fail, 11, pp. 200-205, (2005)

[8]

Schrier R.W., Abraham W.T., Hormones and hemodynamics in heart failure, N Engl J Med, 341, pp. 577-585, (1999)

[9]

Gheorghiade M., Zannad F., Sopko G., Et al., Acute heart failure syndromes: Current state and framework for future research, Circulation, 112, pp. 3958-3968, (2005)

[10]

Gheorghiade M., De Luca L., Fonarow G.C., Et al., Pathophysiologic targets in the early phase of acute heart failure syndromes, Am J Cardiol, 96, (2005)

← 1 2 3 4 5 →